ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0994

Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus

Michelle Petri1, Daniel Joyce2, Kristin Haag2, Andrea Fava3, Daniel W. Goldman1, Diana Zhong2, Shaoming Xiao4, Aaron M. Milstone2 and Laurence S Magder5, 1Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Baltimore, MD, 4Johns Hopkins School of Public Health, Baltimore, MD, 5University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD

Meeting: ACR Convergence 2022

Keywords: COVID-19, immunology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE), and immunosuppressive medications including corticosteroids impact the risk. Furthermore, immunosuppressive medications may reduce the effectiveness of COVID-19 vaccination. Consensus documents have suggested management strategies on handling immunosuppressive medications to increase vaccine efficacy, but the benefit of such strategies has not been proven.

Methods: We collected information on COVID infection, COVID vaccination history, and COVID antibodies in the Hopkins Lupus Cohort, a longitudinal cohort with structured quarterly visits. A cohort of healthcare workers was used for comparison. SARS-CoV-2 IgG was measured by ELISA (Euroimmun). We included only those receiving either a Pfizer or Moderna vaccination and excluded those with a history of COVID infection. Outcome measures included: SARS-CoV-2 antibody IgG levels after vaccination over time in both cohorts; and effect of immunosuppressive medications on post-vaccine IgG levels in SLE patients.

Results: The analysis was based on 334 SLE patients (196 Pfizer, 138 Moderna) and 1887 health care workers (1530 Pfizer and 357 Moderna). SLE patients on immunosuppressive medications had lower post-vaccine IgG levels than SLE patients who were not; but both groups had lower levels than healthcare workers (Figure 1 and Table 1). Holding mycophenolate for one week after vaccine increased post-vaccine IgG levels significantly. In multiple variable models, mycophenolate mofetil, tacrolimus, and belimumab all significantly reduced antibody response to vaccination (Table 2).

Conclusion: SLE patients, regardless of background immunosuppressive therapy, had lower vaccine IgG levels than healthcare workers. Belimumab, tacrolimus and mycophenolate use significantly reduced IgG response to vaccine. Holding mycophenolate for one week improved vaccine efficacy, providing clinical benefit on vaccine response, without leading to clinical flares.

Supporting image 1

Figure 1: Estimated mean IgG measure over time since 2nd vaccination (based on Loess smoothing), by cohort and use of immunosuppressants (IS).

Supporting image 2

Table 1: Effect of medications taken at the time of first vaccination on SARS-CoV_2 IgG levels among SLE patients.

Supporting image 3

Table 2: Estimated effect of treatment at time of vaccination on mean IgG based on a multivariable regression model


Disclosures: M. Petri, Exagen, AstraZeneca, Alexion, Amgen, AnaptysBio, Argenx, Aurinia, Biogen, Caribou Biosciences, CVS Health, EMD Serono, Eli Lilly, Emergent Biosolutions, GlaxoSmithKline (GSK), IQVIA, Janssen, Kira Pharmaceuticals, MedShr, Sanofi, SinoMab, Thermofisher, BPR Scientific Advisory Committee; D. Joyce, None; K. Haag, None; A. Fava, Sanofi; D. Goldman, None; D. Zhong, None; S. Xiao, None; A. Milstone, Merck; L. Magder, None.

To cite this abstract in AMA style:

Petri M, Joyce D, Haag K, Fava A, Goldman D, Zhong D, Xiao S, Milstone A, Magder L. Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/effect-of-immunosuppression-on-covid-vaccination-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-immunosuppression-on-covid-vaccination-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology